VIP (Etoposide, Ifosfamide, Cisplatin) in Adult Patients With Recurrent or Refractory Ewing Sarcoma Family of Tumors

@article{ElWeshi2004VIPI,
  title={VIP (Etoposide, Ifosfamide, Cisplatin) in Adult Patients With Recurrent or Refractory Ewing Sarcoma Family of Tumors},
  author={Amr N. El Weshi and Muhammad Ali Memon and Madras A. Raja and Shouki Bazarbashi and Mohamed M. Rahal and M el Foudeh and Chandrashekhar Pai and Ayman A. Allam and Ibrahim M El Hassan and Adnan A. Ezzat},
  journal={American Journal of Clinical Oncology},
  year={2004},
  volume={27},
  pages={529-534}
}
Despite the fact that Ewing sarcoma family of tumors (ET) is chemosensitive, long-term survival is extremely rare for patients with primary refractory or recurrent disease. There is no standard salvage chemotherapy regimen available in this context. In this study the authors reviewed their experience with the combination of etoposide, ifosfamide, and cisplatin in adult patients with recurrent or refractory disease. From February 1997 through December 2001, they evaluated the efficacy of… 

VIP (etoposide, ifosfamide, and cisplatin) in patients with previously treated soft tissue sarcoma

Outcomes of treatment with VIP (combination of etoposide, ifosfamide, and cisplatin) in patients with previously treated soft tissue sarcoma (STS) are retrospectively reviewed and it is suggested that VIP might be effective in patientsWith previously treated STS.

Single-Centre Experience of Systemic Treatment with Vincristine, Ifosfamide, and Doxorubicin Alternating with Etoposide, Ifosfamide, and Cisplatin in Adult Patients with Ewing Sarcoma

This report retrospectively evaluated the response rates, outcome, and tolerance of adult patients treated with VIA/VIP between 1990 and 2014 and described the experience with the alternating use of triple combination therapies based on vincristine, ifosfamide, and doxorubicin (VIA) and an etoposide, ifo, and cisplatin combination (VIP).

Survival and prognostic factors in adult patients with recurrent or refractory ewing sarcoma family tumours: a 13-years retrospective study in Turkey.

In primary refractory or relapsed ESFT, the presence of extrapulmonary metastases and treatment with salvage regimens other than ifosfamide and etoposide and/or carboplatin correlate with a poor prognosis.

Treatment of adult patients with Ewing’s sarcoma: compliance with chemotherapy protocols & toxicity

A multidisciplinary approach including multi-agent chemotherapy for a prolonged period of time is appropriate in adult patients with ESFT, and dose intensity of chemotherapy should be determined according to the patient’s clinical status and comorbidities.

Etoposide and carbo‐or cisplatin combination therapy in refractory or relapsed Ewing sarcoma: A large retrospective study

This work investigated the outcome of the combination treatment for patients with advanced Ewing sarcoma in progression after standard treatment and found no published data available yet.

Prediction of response and prognostic factors for Ewing family of tumors in a low incidence population

A non-pelvic primary tumor was a favorable predictor of responsiveness to chemotherapy, and Chemo-resistant patients might less benefit from second line chemotherapy.

Extraosseous Ewing Sarcoma: Diagnosis, Prognosis and Optimal Management

Pat characteristics and outcomes seem to be different in EES compared to patients with skeletal Ewing sarcoma, with implications for patient care and prognosis, and multimodality therapeutic strategies are recommended for all types of the Ewing tumour family.

Primary paraesophageal Ewing’s sarcoma: an uncommon case report and literature review

An uncommon case of primary paraesophageal Ewing’s sarcoma in a 25-year-old male harboring the infrequent EWSR1/ERG fusion transcript with multiple splice variants coexisting in the same tumor is reported.

Effect of chemotherapy and radiation therapy on the swallowing of patients with head and neck cancer.

Severity of swallowing difficulty was increased after the Chemotherapy and Radiation therapy, and patients with head and neck cancer and Glasgow coma scale score above 10 had severe dysphagia.

References

SHOWING 1-10 OF 30 REFERENCES

Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide.

Ifosfamide combination chemotherapy as third-line or greater therapy can produce durable complete remissions in heavily pretreated patients with recurrent germ cell tumors.

Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults.

  • J. MiserT. Kinsella I. Magrath
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1987
At the present time, only seven of the 43 patients who responded to the chemotherapy regimen have relapsed, with a median follow-up of 10 weeks after the response.

DICE (dexamethasone, ifosfamide, cisplatin, etoposide) as salvage therapy in non-Hodgkin's lymphomas.

A study of DICE in thirty six patients with intermediate or high-grade non-Hodgkin's lymphomas, finding that response to prior chemotherapy was the only baseline characteristic statistically predictive of response to DICE by logistic regression analysis.

High-dose ifosfamide with mesna uroprotection in Ewing's sarcoma

At present, Kaplan-Meier disease-free survival projects that disease- free survival in patients with large primary tumors has improved compared with that reported for the previous CESS 81 trial.

Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study.

  • R. SaylorsK. Stine T. Vietti
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2001
The combination of cyclophosphamide and topotecan is active in rhabdomyosarcoma, neuroblastoma, and Ewing's sarcoma and can be given with acceptable hematopoietic toxicity with the use of filgrastim support.

Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing's sarcoma.

Myeloblative therapy with hyper-ME +/- C radiochemotherapy can improve the prognosis of multifocal primary and early or multiple relapsing Ewing's sarcoma.

High-dose melphalan +/- total body irradiation and autologous hematopoietic stem cell rescue for adult patients with Ewing's sarcoma or peripheral neuroectodermal tumor.

In conclusion, HDM +/- TBI did not obviously improve the outcome of these 13 patients relative to that expected following conventional dose therapy alone.

Ifosfamide-containing chemotherapy in Ewing's sarcoma: The Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study.

  • A. CraftS. Cotterill I. Lewis
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1998
The 5-year survival rate of 62% is improved compared with the 44% survival rate achieved in ET-1, probably caused by the use of higher doses of ifosfamide compared with relatively low doses of cyclophosphamide inET-1.